ReviewSeminars in immunopathology2014
Microbiota and nonalcoholic steatohepatitis.
Review in Seminars in immunopathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 42 citations in OpenAlex.
- Effect ofFEMS microbes · 2025Article
- Article
- Expression of STING in Women with Morbid Obesity and Nonalcoholic Fatty Liver Disease.Metabolites · 2023Article
- New Insights of OLFM2 and OLFM4 in Gut-Liver Axis and Their Potential Involvement in Nonalcoholic Fatty Liver Disease.International journal of molecular sciences · 2022Article
- Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis.BMC gastroenterology · 2020Article
- Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.BioMed research international · 2019Review
- Periodontitis and Non-alcoholic Fatty Liver Disease, a population-based cohort investigation in the Study of Health in Pomerania.Journal of clinical periodontology · 2017Article
- Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease.Children (Basel, Switzerland) · 2017Review
- Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis.World journal of hepatology · 2016Article
- Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet.International journal of molecular sciences · 2016Review
- Involvement of resistin-like molecule β in the development of methionine-choline deficient diet-induced non-alcoholic steatohepatitis in mice.Scientific reports · 2016Article
- Gut Microbiota and Host Reaction in Liver Diseases.Microorganisms · 2015Review
- Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.World journal of gastroenterology · 2014Review
- Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota.Scientific reports · 2014Article
- Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.Global advances in health and medicine · 2014Article
- Non-alcoholic fatty liver disease, diet and gut microbiota.EXCLI journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent rise in obesity-related diseases, such as nonalcoholic fatty liver disease and its strong association with microbiota, has elicited interest in the underlying mechanisms of these pathologies. Experimental models have highlighted several mechanisms connecting microbiota to the development of liver dysfunction in nonalcoholic steatohepatitis (NASH) such as increased energy harvesting from the diet, small intestine bacterial overgrowth, modulation of the intestinal barrier by glucagon-like peptide-2 secretions, activation of innate immunity through the lipopolysaccharide-CD14 axis caused by obesity-induced leptin, periodontitis, and sterile inflammation. The manipulation of microbiota through probiotics, prebiotics, antibiotics, and periodontitis treatment yields encouraging results for the treatment of obesity, diabetes, and NASH, but data in humans is scarce.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.